Trial Profile
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Leucoplakia
- Focus Therapeutic Use
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress.
- 14 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Sep 2022.